Logo image of NVCT

NUVECTIS PHARMA INC (NVCT) Stock Fundamental Analysis

NASDAQ:NVCT - Nasdaq - US67080T1088 - Common Stock - Currency: USD

8.89  +0.06 (+0.68%)

Fundamental Rating

2

NVCT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 559 industry peers in the Biotechnology industry. NVCT has a great financial health rating, but its profitability evaluates not so good. NVCT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NVCT has reported negative net income.
NVCT had a negative operating cash flow in the past year.
NVCT had negative earnings in each of the past 5 years.
NVCT had a negative operating cash flow in each of the past 5 years.
NVCT Yearly Net Income VS EBIT VS OCF VS FCFNVCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

NVCT's Return On Assets of -66.87% is on the low side compared to the rest of the industry. NVCT is outperformed by 62.61% of its industry peers.
The Return On Equity of NVCT (-96.22%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -66.87%
ROE -96.22%
ROIC N/A
ROA(3y)-103.89%
ROA(5y)N/A
ROE(3y)-170.77%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NVCT Yearly ROA, ROE, ROICNVCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

NVCT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NVCT Yearly Profit, Operating, Gross MarginsNVCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

NVCT has more shares outstanding than it did 1 year ago.
There is no outstanding debt for NVCT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NVCT Yearly Shares OutstandingNVCT Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M 15M
NVCT Yearly Total Debt VS Total AssetsNVCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

NVCT has an Altman-Z score of 8.50. This indicates that NVCT is financially healthy and has little risk of bankruptcy at the moment.
NVCT has a better Altman-Z score (8.50) than 84.79% of its industry peers.
NVCT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.5
ROIC/WACCN/A
WACCN/A
NVCT Yearly LT Debt VS Equity VS FCFNVCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 10M -10M

2.3 Liquidity

NVCT has a Current Ratio of 3.28. This indicates that NVCT is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of NVCT (3.28) is worse than 62.79% of its industry peers.
A Quick Ratio of 3.28 indicates that NVCT has no problem at all paying its short term obligations.
NVCT has a Quick ratio of 3.28. This is in the lower half of the industry: NVCT underperforms 60.82% of its industry peers.
Industry RankSector Rank
Current Ratio 3.28
Quick Ratio 3.28
NVCT Yearly Current Assets VS Current LiabilitesNVCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

NVCT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.86%, which is quite good.
EPS 1Y (TTM)19.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

NVCT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.54% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y1.73%
EPS Next 2Y-0.88%
EPS Next 3Y8.54%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NVCT Yearly Revenue VS EstimatesNVCT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 5M 10M 15M
NVCT Yearly EPS VS EstimatesNVCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NVCT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NVCT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NVCT Price Earnings VS Forward Price EarningsNVCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NVCT Per share dataNVCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.88%
EPS Next 3Y8.54%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NVCT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NUVECTIS PHARMA INC

NASDAQ:NVCT (6/12/2025, 1:09:17 PM)

8.89

+0.06 (+0.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/bmo
Earnings (Next)N/A N/A
Inst Owners6.77%
Inst Owner Change65.87%
Ins Owners44.38%
Ins Owner Change6.8%
Market Cap210.07M
Analysts83.33
Price Target19.38 (118%)
Short Float %16.63%
Short Ratio14.77
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-21.86%
Min EPS beat(2)-39.5%
Max EPS beat(2)-4.21%
EPS beat(4)2
Avg EPS beat(4)-8.75%
Min EPS beat(4)-39.5%
Max EPS beat(4)6.75%
EPS beat(8)3
Avg EPS beat(8)-5.08%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)16.92%
PT rev (3m)1.79%
EPS NQ rev (1m)-3.66%
EPS NQ rev (3m)-10.87%
EPS NY rev (1m)-6.09%
EPS NY rev (3m)-12.96%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 10.03
P/tB 10.03
EV/EBITDA N/A
EPS(TTM)-1.13
EYN/A
EPS(NY)-1.13
Fwd EYN/A
FCF(TTM)-0.51
FCFYN/A
OCF(TTM)-0.51
OCFYN/A
SpS0
BVpS0.89
TBVpS0.89
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -66.87%
ROE -96.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-103.89%
ROA(5y)N/A
ROE(3y)-170.77%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.28
Quick Ratio 3.28
Altman-Z 8.5
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8%
EPS Next Y1.73%
EPS Next 2Y-0.88%
EPS Next 3Y8.54%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y9.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-53.73%
EBIT Next 3Y-30.53%
EBIT Next 5YN/A
FCF growth 1Y20.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.95%
OCF growth 3YN/A
OCF growth 5YN/A